CIK 0001638097
- Non-accelerated filer
- Smaller reporting company
Entera Bio Ltd.
Sign in to watch- Ticker
- ENTX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- Israel
- Entity type
- Operating
- Phone
- +972 25327151
- Business address
- KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM, Israel, 9112002
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Chief Financial Officer bought 56,580 shares at an average $0.53 ($29,847)
- 4 Open-market buy Director bought 50,000 shares at an average $0.57 ($28,460)
- 4 Open-market buy Director bought 30,000 shares at $0.53 ($15,900)
- 4 Open-market buy Chief Executive Officer bought 50,000 shares at $0.53 ($26,585)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3/A Insider 3/A
- 4/A Insider Changes in Ownership
- 4 Open-market buy Director bought 14,900 shares at $1.64 ($24,406)
- 4 Open-market buy Director bought 19,491 shares at $1.68 ($32,803)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy Director bought 10,000 shares at $2.74 ($27,378)
- 4 Open-market buy U.S.based CFO bought 10,000 shares at $2.44 ($24,364)
- 4 Open-market buy Chief Executive Officer bought 10,000 shares at $2.85 ($28,500)
- 4 Open-market buy President of R&D bought 10,000 shares at $2.53 ($25,250)
Page 5 of 7 · 126 filings